Lupus is a poorly-understood autoimmune disorder that is characterised by joint pain and swelling, rashes on the skin and extreme fatigue, with some patients experiencing intermittent flare-ups which can lead to severe and even life-threatening symptoms.
GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product – which was approved as in one-hour infusion formulation for SLE in 2011, the first new therapy for the disease in five decades.
{iframe}http://www.pmlive.com/pharma_news/gsk_and_az_drugs_impress_in_lupus_trials_862181{/iframe}